The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens

NCT02413021 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Acute Lymphoid Leukemia

Interventions

DRUG: Cytarabine
DRUG: Deferasirox

Sponsor

Isfahan University of Medical Sciences